Move to topTop

TOKYO, JAPAN - December 11, 2019 - Terumo Corporation (TSE: 4543) today announced that a new osteoporosis medication, Teribone™ 28.2㎍ subcutaneous autoinjector, has launched in the Japanese market for patients with a high risk of fractures. Terumo has signed a development and manufacturing contract with Asahi Kasei Pharma Corporation. The product will be manufactured at Terumo Yamaguchi D&D Corporation, and marketed by Asahi Kasei Pharma.

Asahi Kasei Pharma has been providing lyophilized vial formulation Teribone™ 56.5㎍ subcutaneous injection, since 2011. This new product offers a new treatment option for patients. The product design enables patients to easily self-inject in a home setting.

Teribone™ 28.2㎍ is pre-filled in Terumo's PLAJEX™ silicone oil-free syringe. The highly breakage-resistant polymer material and the low-reactive and stable characteristic of the syringe played a role in the design of this new product, which is safe for self-injection. The product is assembled with a 2-step autoinjector. Patients simply remove the cap and press the device onto the skin to complete the injection. The single dose use medication is also suitable for elderly patients on continual treatment.

Terumo will continue to strive for expansion of their CDMO business to provide new solutions for pharmaceutical companies, and so contribute to better healthcare.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

Contact us

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

News TOP